AroCell AB (AROC) - Net Assets
Based on the latest financial reports, AroCell AB (AROC) has net assets worth Skr108.87 Million SEK (≈ $11.72 Million USD) as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr122.88 Million ≈ $13.22 Million USD) and total liabilities (Skr14.01 Million ≈ $1.51 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AROC tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr108.87 Million |
| % of Total Assets | 88.6% |
| Annual Growth Rate | 31.65% |
| 5-Year Change | 115.43% |
| 10-Year Change | 66.73% |
| Growth Volatility | 120.66 |
AroCell AB - Net Assets Trend (2007–2024)
This chart illustrates how AroCell AB's net assets have evolved over time, based on quarterly financial data. See AROC defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for AroCell AB (2007–2024)
The table below shows the annual net assets of AroCell AB from 2007 to 2024. For live valuation and market cap data, see AROC company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr121.20 Million ≈ $13.04 Million |
-25.94% |
| 2023-12-31 | Skr163.65 Million ≈ $17.61 Million |
-26.52% |
| 2022-12-31 | Skr222.69 Million ≈ $23.97 Million |
+2.41% |
| 2021-12-31 | Skr217.45 Million ≈ $23.40 Million |
+286.52% |
| 2020-12-31 | Skr56.26 Million ≈ $6.05 Million |
-30.03% |
| 2019-12-31 | Skr80.41 Million ≈ $8.65 Million |
+47.50% |
| 2018-12-31 | Skr54.51 Million ≈ $5.87 Million |
+16.78% |
| 2017-12-31 | Skr46.68 Million ≈ $5.02 Million |
-26.44% |
| 2016-12-31 | Skr63.46 Million ≈ $6.83 Million |
-12.70% |
| 2015-12-31 | Skr72.69 Million ≈ $7.82 Million |
+103.50% |
| 2014-12-31 | Skr35.72 Million ≈ $3.84 Million |
+126.49% |
| 2013-12-31 | Skr15.77 Million ≈ $1.70 Million |
+55.38% |
| 2012-12-31 | Skr10.15 Million ≈ $1.09 Million |
+111.60% |
| 2011-12-31 | Skr4.80 Million ≈ $516.22K |
+298.14% |
| 2010-12-31 | Skr1.20 Million ≈ $129.66K |
+303.52% |
| 2009-12-31 | Skr-592.00K ≈ $-63.71K |
-201.02% |
| 2008-12-31 | Skr586.00K ≈ $63.06K |
-48.14% |
| 2007-12-31 | Skr1.13 Million ≈ $121.61K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to AroCell AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34284600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr23.04 Million | 19.01% |
| Other Components | Skr441.01 Million | 363.87% |
| Total Equity | Skr121.20 Million | 100.00% |
AroCell AB Competitors by Market Cap
The table below lists competitors of AroCell AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lexaria Bioscience Corp
NASDAQ:LEXX
|
$13.39 Million |
|
Sarama Resource
V:SWA
|
$13.40 Million |
|
Thanasiri Group Public Company Limited
BK:THANA
|
$13.40 Million |
|
BioLineRx Ltd
NASDAQ:BLRX
|
$13.41 Million |
|
Imexhs Ltd
AU:IME
|
$13.39 Million |
|
Melbana Energy Ltd
AU:MAY
|
$13.38 Million |
|
Young Heung I&
KO:012160
|
$13.38 Million |
|
Mynd.ai, Inc.
NYSE MKT:MYND
|
$13.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AroCell AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 163,646,000 to 121,198,000, a change of -42,448,000 (-25.9%).
- Net loss of 42,449,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-42.45 Million | -35.02% |
| Other Changes | Skr1.00K | +0.0% |
| Total Change | Skr- | -25.94% |
Book Value vs Market Value Analysis
This analysis compares AroCell AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.03x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.23x to 1.03x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | Skr0.24 | Skr0.54 | x |
| 2011-12-31 | Skr0.57 | Skr0.54 | x |
| 2012-12-31 | Skr0.69 | Skr0.54 | x |
| 2013-12-31 | Skr0.82 | Skr0.54 | x |
| 2014-12-31 | Skr1.46 | Skr0.54 | x |
| 2015-12-31 | Skr2.45 | Skr0.54 | x |
| 2016-12-31 | Skr2.14 | Skr0.54 | x |
| 2017-12-31 | Skr1.57 | Skr0.54 | x |
| 2018-12-31 | Skr1.34 | Skr0.54 | x |
| 2019-12-31 | Skr2.00 | Skr0.54 | x |
| 2020-12-31 | Skr0.75 | Skr0.54 | x |
| 2021-12-31 | Skr2.22 | Skr0.54 | x |
| 2022-12-31 | Skr1.03 | Skr0.54 | x |
| 2023-12-31 | Skr0.71 | Skr0.54 | x |
| 2024-12-31 | Skr0.53 | Skr0.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AroCell AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -73.91%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.11x
- Recent ROE (-35.02%) is above the historical average (-40.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -178.64% | -8014.58% | 0.01x | 3.02x | Skr-2.27 Million |
| 2011 | -74.72% | 0.00% | 0.00x | 1.46x | Skr-4.06 Million |
| 2012 | -31.10% | 0.00% | 0.00x | 1.18x | Skr-4.17 Million |
| 2013 | -23.67% | 0.00% | 0.00x | 1.14x | Skr-5.31 Million |
| 2014 | -17.83% | 0.00% | 0.00x | 1.08x | Skr-9.94 Million |
| 2015 | -10.29% | -1625.10% | 0.01x | 1.02x | Skr-14.75 Million |
| 2016 | -14.55% | -16911.96% | 0.00x | 1.05x | Skr-15.58 Million |
| 2017 | -37.00% | -3440.16% | 0.01x | 1.06x | Skr-21.94 Million |
| 2018 | -38.08% | -2654.89% | 0.01x | 1.05x | Skr-26.21 Million |
| 2019 | -20.15% | -3659.83% | 0.00x | 1.14x | Skr-24.24 Million |
| 2020 | -34.59% | -23165.48% | 0.00x | 1.07x | Skr-25.08 Million |
| 2021 | -23.43% | -417.02% | 0.05x | 1.07x | Skr-71.38 Million |
| 2022 | -26.48% | -159.45% | 0.16x | 1.06x | Skr-81.24 Million |
| 2023 | -36.23% | -137.78% | 0.25x | 1.07x | Skr-75.66 Million |
| 2024 | -35.02% | -73.91% | 0.43x | 1.11x | Skr-54.57 Million |
Industry Comparison
This section compares AroCell AB's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $98,029,514
- Average return on equity (ROE) among peers: -25.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AroCell AB (AROC) | Skr108.87 Million | -178.64% | 0.13x | $13.39 Million |
| Immunovia publ AB (IMMNOV) | $276.63 Million | -5.32% | 0.02x | $13.88 Million |
| Prostatype Genomics AB (PROGEN) | $28.29 Million | -61.53% | 0.19x | $4.09 Million |
| SenzaGen AB (SENZA) | $67.61 Million | -32.68% | 0.44x | $17.46 Million |
| Vimian Group AB (VIMIAN) | $19.59 Million | -4.03% | 0.70x | $1.68 Billion |
About AroCell AB
AroCell AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cell; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as Xi Bao Research AB… Read more